Nikola Reinhard Dürr

Nikola Reinhard Dürr

Auto-generated profile, based on publicly available information

Nikola Reinhard Dürr

Clinic for Radiology and Neuroradiology (N.R.D., F.B., M.S.-H., K.S.)

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2023 in American Journal of Neuroradiology
Verified
Journal Article
Open access
PDF file
SSSimone Schwarz
Simone Schwarz
FNF. Brevis Nuñez
F. Brevis Nuñez
NDN.R. Dürr
N.R. Dürr
FBFriedhelm Brassel
Friedhelm Brassel
MSM. Schlunz-Hendann
M. Schlunz-Hendann
NBNora Bruns
Nora Bruns
BACKGROUND AND PURPOSE: Vein of Galen malformation is a rare congenital cerebrovascular malformation. In affected patients, increased cerebral venous pressure constitutes an important etiologic factor for the development of brain parenchymal damage. The aim of this study was to investigate the potential of serial cerebral venous Doppler measurements to detect and monitor increased cerebral venous pressure. MATERIALS AND METHODS: This was a retrospective monocentric analysis of ultrasound examinations within the first 9 months of life in patients with vein of Galen malformation admitted at <28 days of life. Categorization of perfusion waveforms in the superficial cerebral sinus and veins into 6 patterns was based on antero- and retrograde flow components. We performed an analysis of flow profiles across time and correlation with disease severity, clinical interventions, and congestion damage on cerebral MR imaging. RESULTS: The study included 44 Doppler ultrasound examinations of the superior sagittal sinus and 36 examinations of the cortical veins from 7 patients. Doppler flow profiles before interventional therapy correlated with disease severity determined by the Bicêtre Neonatal Evaluation Score (Spearman ρ = −0.97, P = < .001). At this time, 4 of 7 patients (57.1%) showed a retrograde flow component in the superior sagittal sinus, whereas after embolization, none of the 6 treated patients presented with a retrograde flow component. Only patients with a high retrograde flow component (equal or more than one-third retrograde flow, n = 2) showed severe venous congestion damage on cerebral MR imaging. CONCLUSIONS: Flow profiles in the superficial cerebral sinus and veins appear to be a useful tool to noninvasively detect and monitor cerebral venous congestion in vein of Galen malformation.

28 October 2021 in Neuropediatrics
Verified
Conference Paper
Closed access
PVPia Vaassen
Pia Vaassen
NDNikola Reinhard Dürr
Nikola Reinhard Dürr
TRThorsten Rosenbaum
Thorsten Rosenbaum
Background: Neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PNF) are congenital peripheral nerve sheath tumors with highest growth rates especially in young children. They significantly contribute to the burden of disease with pain, disfigurement or functional impairment. However, in most cases surgery cannot achieve complete tumor removal, carries a high risk of postoperative deficits and does not prevent tumor regrowth. Therefore, the recent approval of the MEK inhibitor selumetinib for the treatment of plexiform neurofibromas provides a long-awaited novel therapeutic option. Methods: Here, we reported our experience with MEK inhibitor treatment in 12 pediatric NF1 patients with inoperable and symptomatic plexiform neurofibromas with progressive growth. They presented with facial, cervical, thoracic, retroperitoneal, and intrahepatic tumors and were treated over periods from 3 to 24 months. Results: Volumetric MRI after 6 months of MEK inhibitor treatment demonstrated a median tumor volume reduction of 30.6% in all patients. In addition, the majority of patients reported clinical benefit such as less pain, improved range of motion or reduced disfigurement. Therapy-related side-effects occurred in 42% of treated children, appeared to be more severe in adolescents as in younger children and mainly consisted of skin toxicity, paronychia and gastrointestinal symptoms. Only 2 patients decided to discontinue MEK inhibitor treatment after severe skin toxicity occurred and no further reduction of tumor size was observed. Conclusion: All NF1 patients showed a tumor reduction between 20 and 55.7% after MEK inhibitor treatment. MEK inhibition is a novel therapeutic approach for inoperable PNF with high efficacy and manageable safety profile. Publication Date: 28 October 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany